Inovio Pharmaceuticals Inc (INO)

6.53
0.26 4.15
NASDAQ : Health Care
Prev Close 6.27
Open 6.33
Day Low/High 6.29 / 6.54
52 Wk Low/High 4.50 / 11.69
Volume 1.15M
Avg Volume 752.30K
Exchange NASDAQ
Shares Outstanding 74.32M
Market Cap 455.61M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Inovio And Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP's Ability to Induce Remission Of HIV Infection And End Lifetime Of Drug Therapy

Inovio And Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP's Ability to Induce Remission Of HIV Infection And End Lifetime Of Drug Therapy

Grant will fund therapeutic clinical studies testing PENNVAX-GP with INO-9012 (an IL-12 immune activator) alone and with the addition of a PD-1 checkpoint inhibitor

First Week Of INO November 17th Options Trading

First Week Of INO November 17th Options Trading

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the November 17th expiration.

George Bickerstaff Elected To Inovio's Board Of Directors

George Bickerstaff Elected To Inovio's Board Of Directors

Former Novartis CFO brings finance, fundraising and M&A experience to Inovio

Biotech Premarket Movers: Seres, PTC, Inovio

Biotech Premarket Movers: Seres, PTC, Inovio

Seres Therapeutics, PTC Therapeutics and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Williams-Sonoma Among 5 Earnings Plays That Could Squeeze the Shorts

Williams-Sonoma Among 5 Earnings Plays That Could Squeeze the Shorts

These heavily shorted stocks could get squeezed higher if they report positive earnings this week.

Interesting INO Put And Call Options For April 21st

Interesting INO Put And Call Options For April 21st

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the April 21st expiration.

Inovio's SynCon® WT1 Cancer Antigen Breaks Tolerance, Highlights Potential For Universal Cancer Immunotherapy

Inovio's SynCon® WT1 Cancer Antigen Breaks Tolerance, Highlights Potential For Universal Cancer Immunotherapy

SynCon WT1 and PSMA antigens join hTERT in INO-5401, Inovio's cancer product planned for immuno-oncology combination study 

4 Biotech Stocks on the Move

4 Biotech Stocks on the Move

These four biotech stocks have been moving on some interesting news and clinical results.

Biotech Movers: Cempra Flys High On Phase Three Results

Biotech Movers: Cempra Flys High On Phase Three Results

Other movers include Incyte, Achillion and Inovio.

Hershey, Nvidia, Accenture, Cheniere Energy: 'Mad Money' Lightning Round

Hershey, Nvidia, Accenture, Cheniere Energy: 'Mad Money' Lightning Round

Jim Cramer is bullish on Hershey, Nvidia, Accenture, Cheniere Energy. He's bearish on Emerge Energy and Seaspan.

Stay Long, This Bull Is Strong: Cramer's 'Mad Money' Recap (Wednesday 2/15/17)

Stay Long, This Bull Is Strong: Cramer's 'Mad Money' Recap (Wednesday 2/15/17)

Don't get upended by the rhetoric. The transports are confirming, banks are solid, there's a genuine uptick in commerce and earnings are strong, says Jim Cramer.

Inovio And ApolloBio To Collaborate On Development And Commercialization Of HPV Pre-cancer Immunotherapy VGX-3100 In Greater China

Inovio And ApolloBio To Collaborate On Development And Commercialization Of HPV Pre-cancer Immunotherapy VGX-3100 In Greater China

Inovio to receive up to $50 million in upfront and near term payments and equity investment

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

Jim Cramer names a few of his favorite things: housing, bank, material and tech stocks, oil, copper and deregulation.

Chesapeake Energy, Comcast, Citigroup: 'Mad Money' Lightning Round

Chesapeake Energy, Comcast, Citigroup: 'Mad Money' Lightning Round

Jim Cramer is bullish on Chesapeake Energy and some bank stocks. But he's bearish on Inovio Pharmaceutical.

First Week Of August 2017 Options Trading For Inovio Pharmaceuticals (INO)

First Week Of August 2017 Options Trading For Inovio Pharmaceuticals (INO)

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the August 2017 expiration.

Inovio's Co-Founder And Chair Of Its Scientific Advisory Board Selected As A Top 20 Translational Researcher

Inovio's Co-Founder And Chair Of Its Scientific Advisory Board Selected As A Top 20 Translational Researcher

Dr. David B. Weiner recognized for his innovative medical and scientific research, which has been the basis for over 100 patents

Inovio's Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses In Tumor Tissue And Peripheral Blood In Patients With HPV-Associated Head And Neck Cancer

Inovio's Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses In Tumor Tissue And Peripheral Blood In Patients With HPV-Associated Head And Neck Cancer

Four of five study subjects in treated group show progression free survival ranging from nine to 24 months to date in phase I/IIa clinical study